(Q34029257)

English

Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Gai Ling Li

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Helen Winter

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Rosalin Arends

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Gary W Jay

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Vu Le

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Tim Young

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

John P Huggins

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

1 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

British Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

73

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

706-716

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403198

5 July 2018

Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403198

5 July 2018

Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403198

5 July 2018

The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403198

5 July 2018

Enzymatic pathways that regulate endocannabinoid signaling in the nervous system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403198

5 July 2018

The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403198

5 July 2018

Cognitive testing in early-phase clinical trials: development of a rapid computerized test battery and application in a simulated Phase I study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403198

5 July 2018

Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403198

5 July 2018

Safety issues concerning the medical use of cannabis and cannabinoids

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403198

5 July 2018

Antibody pharmacokinetics and pharmacodynamics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403198

5 July 2018

Biochemical mechanisms of drug action: what does it take for success?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403198

5 July 2018

Modulation of anxiety through blockade of anandamide hydrolysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403198

5 July 2018

Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403198

5 July 2018

Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403198

5 July 2018

Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403198

5 July 2018

The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403198

5 July 2018

A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403198

5 July 2018

Pharmacologic target-mediated drug disposition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403198

5 July 2018

Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04137.X

21 January 2018

Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04137.X

21 January 2018

Characterization of the sleep-wake patterns in mice lacking fatty acid amide hydrolase

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04137.X

21 January 2018

Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04137.X

21 January 2018

Endogenous ethanolamide analysis in human plasma using HPLC tandem MS with electrospray ionization.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04137.X

21 January 2018

Cognitive testing in early phase clinical trials: outcome according to adverse event profile in a Phase I study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2011.04137.X

21 January 2018

High-performance liquid chromatography-tandem mass spectrometry assay of fatty acid amide hydrolase (FAAH) in blood: FAAH inhibition as clinical biomarker

1 reference

https://pubmed.ncbi.nlm.nih.gov/22044402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2125.2011.04137.X

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34029257&oldid=1963648671"